Abstract Chimetic antigen receptor T cells (CAR-T) are a kind of novel killer cells derived from autogenous or allogeneic T cells targeting the tumor specific antigens by gene engineering transpormation. The CAR-T cells possess the advantages of high specificity, high efficiency and non-MHC restriction, thus achieving good therapeutic effects in relapsed/refractory hematological tumors and some solid tumors. The process of CAR-T cell preparation includes cell isolation and purification, activation and differentiation, gene modification, in vitro amplification, phenotypic quality control, preservation and reinfusion. In recent years, with the rapid development of flow cytometry, this technology has been widely used in all aspects of CAR-T cell therapy, including pre-treatment screening, in vitro preparation and post-transfusion monitoring, which plays an important role in its innovative optimization.
题目: 流式细胞术在CAR-T细胞治疗中的应用进展.
摘要: 嵌合抗原受体T细胞（chimeric antigen receptor T cell，CAR-T）是通过基因工程技术将自体或异体T细胞改造成针对肿瘤特异性抗原的新型杀伤细胞，具有特异性强、效率高、非MHC限制等优点，在复发/难治性血液系统肿瘤和部分实体瘤中取得了良好的治疗效果。CAR-T细胞制备流程包括细胞分离和纯化、活化和分化、基因修饰、体外扩增、表型质控、保存和回输。近年来，随着流式细胞术的迅速发展，使其广泛应用于CAR-T细胞治疗的各个环节，包括治疗前筛查、体外制备和回输后监测，并在其创新优化过程中发挥着重要的作用.